For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

REGINA, SASKATCHEWAN / ACCESS Newswire / June 16, 2025 / Consumer Choice Award (CCA) is proud to announce that Affordable ...

TRNR is expected to have the largest US publicly listed crypto treasury focused on an AI-token TRNR began acquiring $FET in ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...